Skip to content

Haemonetics HAE Trademarks

Trademarks at other companies

Abbott logo
AbbottABT
Boston Scientific logo
Boston ScientificBSX
ICU Medical logo
ICU MedicalICUI

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's trademarks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's trademarks?
Haemonetics (HAE) reported trademarks of $5.49M in Q4 2025.
How has Haemonetics's trademarks changed year-over-year?
Haemonetics's trademarks decreased by 18.7% year-over-year, from $6.75M to $5.49M.
What is the long-term trend for Haemonetics's trademarks?
Over 2 years (2023 to 2025), Haemonetics's trademarks has grown at a -33.0% compound annual growth rate (CAGR), from $20.47M to $9.19M.